Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (September 2013)

29 slides from Sorrento Therapeutics's investor presentation, Sep 11, 2013

  1. Slide 1: Next-Generation Cancer Therapeutics

    Exhibit 99.3 Sorrento Therapeutics, Inc. Next-Generation Cancer Therapeutics September 2013

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement OTCQB: SRNE This presentation contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements regarding expectations, beliefs or intentions regarding our business, technologies and products s

  3. Slide 3: Positioned to Become Oncology Leader

    Positioned to Become Oncology Leader Cynviloq™ Phase 3 Immuno- therapy G-MAB® mAb candidates Targeted ADC/AfDC therapeutics

  4. Slide 4: Sorrento's Next-Generation Cancer Therapeutics

    Sorrento’s Next-Generation Cancer Therapeutics G-MAB® • High-diversity human Ab library • 10+ lead mAb programs, including PD-L1, PD-1, and CCR2 Cynviloq™ TUMOR • FTO and no stacking royalties Next-generation Abraxane® • Bioequivalence (BE) pathway for approval • Efficacy demonstrated • US and EU ri

  5. Slide 5: Pipeline

    Pipeline INDICATION Metastatic Breast Cancer Non-Small Cell Lung Cancer } 505(b)(2) Pathway BE Trial Q4 2013 Q4 2014 / Q1 2015 Cynviloq™ Pancreatic Cancer (BE* or sNDA) Bladder Cancer (sNDA) Ovarian Cancer (sNDA) Multiple INDICATION > TARGET Strategic Oncology > PD-L1, PD-1, CXCR5 H1 2015 G-MAB® Inf

  6. Slide 6: Seasoned Management Team

    Seasoned Management Team Henry Ji, Ph.D. • Inventor of G-MAB ® Technology President, CEO & Director • President & CEO of Stratagene Genomics • VP of CombiMatrix and Stratagene Vuong Trieu, Ph.D. • Founder and CEO of IgDraSol Chief Scientific Officer • Co-inventor of IP covering Abraxane ® • Instrume

  7. Slide 7: Oncology Franchise: Cynviloq

    Oncology Franchise Cynviloq™ Phase 3 7

  8. Slide 8: Cynviloq is the 3rd Generation Paclitaxel Therapy

    Cynviloq™ is the 3rd Generation Paclitaxel Therapy Maximum Tolerated Peak Generation Formulation Dose (MTD) Product Sales st 1 Cremophor EL Taxol ® excipient: 175 mg/m 2 ~ $1.6B (WW in 2000) paclitaxel Polyoxyethylated castor oil nd Biological polymer: 2 260 mg/m 2 $430M Abraxane® Mean size Donor-de

  9. Slide 9: Why Cynviloq?

    Why Cynviloq™? 1. Abraxane® sold to Celgene for > $3 billion 2. Efficacy demonstrated in Phase 2 and Phase 3 studies • Phase 2 studies affirmed clinical activity in MBC, NSCLC, PC, ovarian cancer (OC) and bladder cancer (BC) • Interim data from Phase 3 study in MBC patients shows activity comparable

  10. Slide 10: Cynviloq has Unique Advantages vs. Abraxane

    Cynviloq™ has Unique Advantages vs. Abraxane ® Cynviloq™ Cynviloq™ Abraxane® Taxol ® Advantage Maximum Tolerated Dose Potential for >300 260 175 higher efficacy (mg/m²) Rapid reconstitution: Convenience for busy no foaming concerns practices and pharmacies No donor-derived human No viral / prion con

  11. Slide 11: Cynviloq is Efficacious

    Cynviloq™ is Efficacious Phase 3 study in MBC Summary of Clinical Exposures Stage Trial Patients Phase 1 MTD 80 MBC, NSCLC, Phase 2 259 PC, OC, BC Phase 3 MBC 105 Post Market MBC, NSCLC 502 (Safety) Total 946 US approval for Abraxane ® in MBC and NSCLC for non-inferiority against Taxol ® based on OR

  12. Slide 12: Common Mechanism Of Action

    Common Mechanism Of Action Cynviloq™ ® • Cynviloq™ and Abraxane Intact nanoparticle (in the vial) nanoparticles disintegrate g/mL rapidly in the bloodstream to Disintegration release free paclitaxel upon dilution (in blood) Abraxane ® • Free paclitaxel exploits the Intact nanoparticle (in the vial)

  13. Slide 13: Simulated PK Parameters Supportive of BE

    Simulated PK Parameters Supportive of BE: Cynviloq™ vs. Abraxane® Comparison of mean non-compartmental pharmacokinetic parameters of 2 Cynviloq™ (T) and Abraxane® (R) @ 260 mg/m with 30 min infusion time: Cmax Ratio AUCinf Ratio (ng/mL) Cmax(T)/Cmax(R) (ng*h/mL) AUCinf(T)/AUCinf(R) TM Cynviloq 19486

  14. Slide 14: 505(b)(2) Bioequivalence Dev't Pathway

    505(b)(2) Bioequivalence Dev’t Pathway • EOP2 meeting (July 2013): FDA concurrence on 505(b)2 BE as appropriate regulatory submission pathway • Bioequivalence registration study in MBC (Q4 2013) - 12 months of duration (including patient recruitment) - Trial cost less than $5M • Dose 260 mg/m 2 Abra

  15. Slide 15: Potential to Expand Label Indications

    Potential to Expand Label Indications – For Example: 2nd Line Bladder Cancer Cynviloq™ Best Supportive Care Phase 2 (Korea)* Phase 2 (Japan) **/ Phase 3 (EU)*** 260-300 mg/m2 q3w n=23** / n=108*** n=34# Overall Response Rate (ORR) 21% - / 0%*** Progression Free Survival 2.7 M - / 1.5 M*** Overall Su

  16. Slide 16: Cynviloq Market Opportunity

    Cynviloq™ Market Opportunity st ~70,000 patients treated with paclitaxel-based regimen in 1 line st # of Patients Treated in 1 Line (US Only) 100,000 (2012) 90,000 ~55,000 patients with paclitaxel Other regimens st as 1 line therapy in MBC, 80,000 PAC+ treated NSCLC & OC 70,000 60,000 50,000 15,903

  17. Slide 17: Therapeutic Antibody Engine

    Therapeutic Antibody Engine

  18. Slide 18: Top Selling Therapeutic Antibodies

    Top 10 Selling Therapeutic Antibodies (> $50B) 2012 Sales mAb Target Companies (US$ billions)* US Global Humira (Adalimumab) TNF Abbott; Esai 4.4 9.3 Enbrel (Etanercept) TNF Amgen; Pfizer; Takeda 4.0 8.0 Rituxan (Rituximab) CD20 Roche 3.3 7.0 Remicade (Infliximab) TNF J&J; Merck; Mitsubishi Tanabe 3

  19. Slide 19: G-MAB Library

    G-MAB® Library • Proprietary amplification • Issued and pending patents - RNA amplification for variable on G-MAB ® library and domains individual mAbs • Very high diversity: • Freedom-to-Operate (FTO) VH: 7.1 x 10 7 VL: 2.9 x 10 8 • No Stacking Royalties Combined: 2.1 x 10 16 Most Difficult Targets

  20. Slide 20: Anti-PD-L1 mAbs Exhibit Potent Activity In Vitro and In Vivo

    Anti-PD-L1 mAbs Exhibit Potent Activity In Vitro and In Vivo In Vitro* In Vivo** Day Competitor mAb Sorrento mAb * mAbs @ 0.05 mg/mL ** xenograft model using H1975 human NSCLC cells; % inhibition relative to control mAb treatment *** p<0.05, mean tumor volumes are significantly reduced in STI-A1010

  21. Slide 21: Naked Anti-Cancer mAbs Exert Potent Anti-Tumor Activity In Vivo

    “Naked” Anti-Cancer mAbs Exert Potent Anti-Tumor Activity In Vivo Anti VEGFR2 mAb* Anti c-Met mAb** 2000 1000 1800 900 1600 800 PBS PBS 1400 700 1200 600 1000 500 800 400 treatment initiated 600 300 Anti-VEGF mAb 400 200 Sorrento mAb 200 100 Sorrento mAb 0 0 5 10 15 20 25 7 14 21 28 35 Days After Tu

  22. Slide 22: Sorrento ADCs Possess Enhanced Cytotoxic Activity

    Sorrento ADCs Possess Enhanced Cytotoxic Activity Compared to “Naked” mAbs Anti-VEGFR2 ADC* Anti-c-Met ADC** p value p value < 0.0001 < 0.0001 IgG Concentration (nM) IgG Concentration (nM) Leading Competitor mAb Toxin Control Sorrento mAb + Toxin * Human Vascular Endothelial Cells (HUVECs) ** agains

  23. Slide 23: Targeted Drug Formulation Platform ADC/AfDC

    Targeted Drug Formulation Platform Targeted ADC/AfDC Therapeutics 23

  24. Slide 24: Antibody Drug Conjugates (ADC)

    Antibody Drug Conjugates (ADC) Key Components: 1. Target-specific internalizing antibody 2. Potent cytotoxic prodrugs 3. Linker and conjugation chemistries Drug released in CANCER CELL 24

  25. Slide 25: Antibody formulated Drug Conjugates (AfDC)

    Antibody formulated Drug Conjugates (AfDC) Key Features: 1. Approved oncolytic drug with known safety profile 2. No internalization required 3. Flexibility in combining mAbs and drugs Drug released in TUMOR 25

  26. Slide 26: G-MAB, ADC and AfDC Pipeline

    G-MAB®, ADC and AfDC Pipeline G-MAB® Antibody PD-L1 (STI-A100X) H1 2015 PD-L1 (STI-A100X) AfDC PD-1 (STI-A110X) Multiple ONCOLOGY VEGFR2-ADC (STI-A0168) H2 2015 EGFR (STI-A020X) ADC/AfDC c-Met (STI-A060X) ADC/AfDC Strategic PD-L1 (STI-B010X) INFLAMMATION RAGE (STI-B120X) CGRP (STI-B150X) Partnership

  27. Slide 27: Positioned to Become Oncology Leader

    Positioned to Become Oncology Leader Cynviloq™ Phase 3 Immuno- therapy G-MAB® mAb candidates Targeted ADC/AfDC therapeutics

  28. Slide 28: Oncology Drug, Antibody Library and ADC Company Valuations

    Small Molecule Oncology Drug, Antibody Library and ADC Company Valuations Company Small Molecule Antibody Targeted Mkt Cap* Oncology Drug Platform Drug Delivery NSCLC, MBC Antibody ADC/ Sorrento: SRNE (Ph3/Registration Trial) Library AfDC $150M Puma: PBYI MBC (Phase 3) ~$1.6B Clovis: CLVS NSCLC, MBC

  29. Slide 29: Sorrento Therapeutics

    Sorrento Therapeutics Next-Generation Cancer Therapeutics Contact: Henry Ji President and CEO [email protected] (858) 668-6923

Sorrento Therapeutics — Investor Presentation (September 2013) on 6ix